Cover Image

Survival according to BRAF-V600 tumor mutations: an analysis of 437 patients with primary melanoma

The prognostic impact of BRAF-V600 tumor mutations in stage I/II melanoma patients has not yet been analyzed in detail. We investigated primary tumors of 437 patients diagnosed between 1989 and 2006 by Sanger sequencing. Mutations were detected in 38.7% of patients and were associated with age, hist...

Full description

Saved in:
Bibliographic Details
Main Authors: Meckbach, Diana (Author) , Bauer, Jürgen (Author) , Pflugfelder, Annette (Author) , Meier, Friedegund (Author) , Busch, Christian (Author) , Eigentler, Thomas (Author) , Capper, David (Author) , Deimling, Andreas von (Author) , Mittelbronn, Michel Guy André (Author) , Perner, Sven Roger (Author) , Ikenberg, Kristian (Author) , Hantschke, Markus (Author) , Gabriel, Petra (Author) , Garbe, Claus (Author) , Weide, Benjamin Matthias (Author)
Format: Article (Journal)
Language:English
Published: January 24, 2014
In: PLOS ONE
Year: 2014, Volume: 9, Issue: 1
ISSN:1932-6203
DOI:10.1371/journal.pone.0086194
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1371/journal.pone.0086194
Verlag, lizenzpflichtig, Volltext: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0086194
Get full text
Author Notes:Diana Meckbach, Jürgen Bauer, Annette Pflugfelder, Friedegund Meier, Christian Busch, Thomas K. Eigentler, David Capper, Andreas von Deimling, Michel Mittelbronn, Sven Perner, Kristian Ikenberg, Markus Hantschke, Petra Büttner, Claus Garbe, Benjamin Weide
Description
Summary:The prognostic impact of BRAF-V600 tumor mutations in stage I/II melanoma patients has not yet been analyzed in detail. We investigated primary tumors of 437 patients diagnosed between 1989 and 2006 by Sanger sequencing. Mutations were detected in 38.7% of patients and were associated with age, histological subtype as well as mitotic rate. The mutational rate was 36.7% in patients with disease-free course and 51.7% in those with subsequent distant metastasis (p = 0.031). No difference in overall survival (p = 0.119) but a trend for worse distant-metastasis-free survival (p = 0.061) was observed in BRAF mutant compared to BRAF wild-type patients. Independent prognostic factors for overall survival were tumor thickness, mitotic rate and ulceration. An interesting significant prognostic impact was observed in patients with tumor thickness of 1 mm or less, with the mutation present in 6 of 7 patients dying from melanoma. In conclusion, no significant survival differences were found according to BRAF-V600 tumor mutations in patients with primary melanoma but an increasing impact of the mutational status was observed in the subgroup of patients with tumor thickness of 1 mm or less. A potential role of the mutational status as a prognostic factor especially in this subgroup needs to be investigated in larger studies.
Item Description:Gesehen am 16.10.2020
Physical Description:Online Resource
ISSN:1932-6203
DOI:10.1371/journal.pone.0086194

Similar Items